Equibles does not estimate personal net worth.
Get an email with a short summary when Phathom Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get PHAT alertsSanjeev Narula is recorded as CFO at Phathom Pharmaceuticals, Inc. (PHAT) since October 6, 2025. Phathom Pharmaceuticals, Inc. reported in an 8-K filed October 6, 2025 that Sanjeev Narula was appointed principal financial officer, effective October 6, 2025. Phathom Pharmaceuticals, Inc. reported in an 8-K filed October 6, 2025 that Sanjeev Narula was appointed Chief Financial and Business Officer, effective October 6, 2025. The proxy statement of Phathom Pharmaceuticals, Inc. reports total compensation of $3,617,962 for Sanjeev Narula in fiscal 2025, including a base salary of $131,442. Sanjeev Narula has spoken on 4 earnings calls and 3 other investor events across 1 company, most recently for Phathom Pharmaceuticals, Inc. on July 30, 2026. Phathom Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Phathom Pharmaceuticals, Inc. includes Steven Basta (CEO and Board Member), Steven L. Basta (CEO and Board Member), Anthony Guzzo (CFO and Chief Accounting Officer) and 7 others.
“Mr. Narula will also serve as principal financial officer of the Company, replacing Robert Breedlove, Vice President, Finance, who will continue to serve as principal accounting officer.”
“Effective October 6, 2025, Sanjeev Narula was appointed as the Chief Financial and Business Officer of Phathom Pharmaceuticals, Inc. (the "Company").”
“I'd like to start by saying how pleased we are with our results and momentum of our revenue trajectory. The business is growing nicely. We remain confident in our path forward.”
“And, Paul, if I can just add one other thing we did beginning of the year. We looked at our cap structure and then realized that, you know, we needed to have some modifications in the cap structure to have more sustainable availability of funds, so we did that.”
“So gross to net, Dennis, we gave a range at the beginning of the year of 55% to 59%. We came at the lower end of the range in the first quarter. It's a function of two things.”
“We have a lot to cover, so let's jump right into our Q1 results. Revenues for Corridor 1 were $58.3 million, reflecting year-on-year growth of 104% and a sequential growth of 1% over Q4 2025.”
“And Joey, one other thing that we, it's a priority for 26, but it's already done. I just do want to talk about the cap structure. There was a lot of, you know, noise about cap structure.”
2025-10-06–present
Proxy statement
Start not stated–present
Last confirmed April 7, 2026
Biotechnology · Healthcare
CFO
2025-10-06–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Phathom Pharmaceuticals, Inc. (PHAT) | Chief Financial and Business Officer | $131,442 | $3,617,962 |
